Total serum tryptase: A predictive marker for KIT mutation in acute myeloid leukemia

Roberto Cairoli, Carla Barbara Ripamonti, Alessandro Beghini, Simonetta Granata, Giovanni Grillo, Matteo Brioschi, Gianpaolo Nadali, Assunta Viola, Chiara Cattaneo, Liliana Inropido, Erika Ravelli, Giambattista Bertani, Laura Pezzetti, Michele Nichelatti, Alessandro Marocchi, Giuseppe Rossi, Giovanni Pizzolo, Felicetto Ferrara, Anna Maria Nosari, Enrica Morra

Research output: Contribution to journalArticlepeer-review


Human tryptase is a serine protease expressed in mast-cells. We previously observed that AML blast cells, cultured in vitro from a KIT D816Y patient, give rise to adherent cells with mast-cell like phenotype and tryptase was released in the serum-free medium. To correlate total serum tryptase (ts-try) levels with cytogenetic features and KIT mutational status, we analyzed serum samples from AML patients at diagnosis. In 70 out of 155 patients (45%) we detected elevated ts-try (>15 ng/mL), significantly linked to t(8;21) (P <.001) and inv(16) (P = .007). In patients that achieved complete remission the ts-try decreased to normal values. In 75 patients screened for KIT mutation, we found a clear relationship between elevated ts-try and mutated patients with t(8;21) (P <.001). In conclusion, we propose that checking for ts-try at diagnosis of AML may be a simple tool to select patients to be addressed to KIT mutation screening.

Original languageEnglish
Pages (from-to)1282-1284
Number of pages3
JournalLeukemia Research
Issue number9
Publication statusPublished - Sep 2009


  • AML
  • KIT
  • Serum tryptase

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Total serum tryptase: A predictive marker for KIT mutation in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this